← The SEC Ephemeris: the whole map
REGENXBIO, Inc. clemidsogene lanparvovee
In the graph: all 5 documents (202 pages).
- Ticker
- RGNX
- Product
- clemidsogene lanparvovee
- Disease area
- Not yet classified
- Response path
- Not yet classified
- Complete Response Letters
- February 7, 2026
From FDA letters and SEC filings. Not investment or medical advice.